TABLE 1.

Member Characteristics

Member characteristics	N = 494a
Mean age at first ELX/TEZ/IVA claim, years (SD)	26.2 (13.4)
Sex, n (%)
Female	234 (47.4)
Male	260 (52.6)
Geographic region, n (%)
South	248 (50.2)
Midwest	168 (34.0)
West	49 (9.9)
Northeast	29 (5.9)
Pancreatic enzyme replacement therapy use during 180-day preperiod, n (%)
Yes	347 (70.2)
No	147 (29.8)
Average ELX/TEZ/IVA claims during 180-day postperiod,a per member (SD)	6.5 (1.7)
Average day supply across ELX/TEZ/IVA claims during 180-day postperioda (SD)	28.2 (3.4)

^aAll members naive to cystic fibrosis transmembrane conductance regulator therapy and newly initiating ELX/TEZ/IVA.

ELX/TEZ/IVA = elexacaftor/tezacaftor/ivacaftor.